Conference Coverage

ACC 2025

Chicago, Illinois

March 29, 2025

March 31, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.

More News

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

More Slides

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

Presentation ACC 2025

Two-year Outcomes Of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The TRILUMINATE Pivotal Trial

Presenter: Saibal Kar

March 30, 2025

Presentation ACC 2025

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Presenter: Joo-Yong Hahn

March 29, 2025

ACC 2025 Conference Wrap-Up

See More Videos

All Conference Content

Advertisement

ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

More News

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

WARRIOR: No Clear Answers on How to Best Treat INOCA

More Slides

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Dapagliflozin after Transcatheter Aortic Valve Implantation

Two-year Outcomes Of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The TRILUMINATE Pivotal Trial

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

ACC 2025 Conference Wrap-Up

@TCTMD

Advertisement

All Conference Content

Advertisement

ACC 2025

More News

More Slides

Sign Up for Our Newsletter

Advertisement

All Conference Content

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content

ACC 2025